Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Advisory Board Appointment

18 Aug 2021 07:00

RNS Number : 9416I
DeepMatter Group PLC
18 August 2021
 

18 August 2021

 

DeepMatter Group Plc

DeepMatter CEO appointed Chairman of Industrial Advisory Board at Imperial College

DeepMatter Group Plc (AIM: DMTR, "DeepMatter", the "Group"), which focuses on digitalising chemistry, announces that its CEO, Mark Warne, has been invited to chair the Industrial Advisory Board (IAB) at Imperial College's EPSRC Centre for Doctoral Training in Next Generation Synthesis & Reaction Technology (CDT), for the next two years.

Mark's principal role will be to liaise closely with the CDT's network of industrial partners, including AstraZeneca, Bayer, BASF, GlaxoSmithKline, IBM, The Janssen Pharmaceutical Companies of Johnson & Johnson, Mettler-Toledo, Syngenta, and Pfizer. 

These partners provide industrial advice and feedback on the CDT's research direction as well as making recommendations in the areas of chemistry, chemical engineering and data science.

Mark Warne, DeepMatter CEO, commented:

"This appointment will enable me to work closely with a number of multinational pharma companies and Key Opinion Leaders - all of whom are committed to integrating chemistry with technology and sharing their expertise and experience with the chemists of the future.

"This appointment is a further validation of DeepMatter's position at the centre of the digitalisation of chemistry and the development of big data and analytics for the chemists in early-stage formulation."

The CDT is made up of a multi-disciplinary team of internationally-leading researchers at Imperial College. It benefits from significant infrastructural and capital investment on its state-of-the-art technology and facilities such as The Centre for Rapid Online Analysis of Reactions (ROAR).

The CDT aims to engage with the Centres of Excellence in the US and Europe, to deliver a unique multi-faceted training programme in order to improve the skills, employability and productivity of the graduates and to equip them for future academic and industrial roles.

Jinata Subba, EPSRC CDT Programme Manager, Dept of Chemistry, Imperial College, added:

 "DeepMatter's knowledge and experience of automation in chemistry will help us on our mission to transform synthetic chemistry into a truly data-driven discipline. Automation enables researchers to gather and share huge amounts of data about chemical reactions, which can then be used to optimize processes and even forecast the outcomes of entirely new reactions.

"There is a skills gap between academic training and the experimental methods used routinely in industry. At Imperial College our programme aims to equip students for the future of synthetic chemistry. The advice and feedback from the Industrial Advisory Board is proving invaluable.

"DeepMatter's mission of digitising chemistry using cutting edge analytical instruments and Machine Learning techniques resonates with the way we are pioneering this approach to training."

 

For more information, please contact:

 

DeepMatter Group PlcMark Warne, Chief Executive Officer 0141 548 8156

Canaccord Genuity Limited (Nominated Advisor and Broker) 020 7523 8000Bobbie Hilliam

Meare Consulting 07990 858548Adrian Duffield

 

About DeepMatter Group Plc 

DeepMatter is building and commercialising the most powerful data platforms, to enable scientists to easily perform and optimise chemical reactions, by increasingly integrating chemistry with technology. Ultimately this will allow the greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics.

Visit: www.deepmatter.io and follow @deepmattergroup

 

About the EPSRC Centre for Doctoral Training in Next Generation Synthesis & Reaction Technology

The mission of the Next Generation Synthesis & Reaction Technology CDT is to educate a critical mass of researchers equipped to respond to future research challenges and opportunities created by the data-revolution. The aim is to train highly qualified researchers with the ability to collect data using automated, high-throughput reaction platforms, and to apply quantitative and statistical approaches to data analysis and utilisation. This will be achieved by incorporating cross-disciplinary skills from engineering, as well as computing, statistics, and informatics into a chemistry graduate programme, which are largely lacking from existing doctoral training in synthetic chemistry.

Visit: www.imperial.ac.uk/next-generation-synthesis-reaction-technology/the-cdt-programme/

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABUGDIBGBDGBR
Date   Source Headline
5th Jan 20237:00 amRNSCancellation - DEEPMATTER GROUP PLC
4th Jan 20238:00 amRNSHolding(s) in Company
29th Dec 20225:30 pmRNSDeepmatter Group
20th Dec 20227:00 amRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
19th Dec 20223:44 pmRNSResult of General Meeting
19th Dec 20222:05 pmRNSSecond Price Monitoring Extn
19th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 202211:05 amRNSSecond Price Monitoring Extn
19th Dec 202211:00 amRNSPrice Monitoring Extension
15th Dec 20224:40 pmRNSSecond Price Monitoring Extn
15th Dec 20224:35 pmRNSPrice Monitoring Extension
15th Dec 20222:05 pmRNSSecond Price Monitoring Extn
15th Dec 20222:00 pmRNSPrice Monitoring Extension
9th Dec 202211:05 amRNSSecond Price Monitoring Extn
9th Dec 202211:00 amRNSPrice Monitoring Extension
8th Dec 20228:46 amRNSHolding(s) in Company
2nd Dec 20227:00 amRNSPosting of Circular
1st Dec 20227:00 amRNSProposed Cancellation of Ordinary Shares
24th Nov 20227:00 amRNSCorporate Update
31st Oct 202212:00 pmRNSDirector/PDMR Shareholding
26th Oct 20227:00 amRNSTrading Update
26th Oct 20227:00 amRNSDeepMatter signs multi-year license agreement
26th Aug 20221:25 pmRNSHolding(s) in Company
25th Aug 20227:00 amRNSHalf Year Results
28th Jun 20227:00 amRNSDeepMatter acquires AI specialist ChemIntelligence
20th Jun 20224:41 pmRNSSecond Price Monitoring Extn
20th Jun 20224:35 pmRNSPrice Monitoring Extension
20th Jun 20222:05 pmRNSSecond Price Monitoring Extn
20th Jun 20222:00 pmRNSPrice Monitoring Extension
20th Jun 202211:05 amRNSSecond Price Monitoring Extn
20th Jun 202211:00 amRNSPrice Monitoring Extension
9th Jun 20225:26 pmRNSHolding(s) in Company
27th May 20222:30 pmRNSResult of AGM
25th May 20222:30 pmRNSIssue of Equity and TVR
23rd May 20227:00 amRNSDirectorate Change
20th May 20227:00 amRNSContract extension
11th May 20227:00 amRNSContract
27th Apr 20227:00 amRNSFinal Results
30th Mar 20224:00 pmRNSHolding(s) in Company
1st Mar 20227:00 amRNSContract
14th Feb 20227:00 amRNSDirector/PDMR Shareholding
26th Jan 20223:20 pmRNSHolding(s) in Company
26th Jan 20223:15 pmRNSHolding(s) in Company
26th Jan 20227:00 amRNSHolding(s) in Company
25th Jan 20225:45 pmRNSHolding(s) in Company
25th Jan 202212:30 pmRNSHolding(s) in Company
25th Jan 20227:00 amRNSDirector/PDMR Shareholding
25th Jan 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.